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ABSTRACT
Polyclonal anti-thymocyte globulin (ATG) administered before allogeneic blood hematopoietic progenitor cell
transplantation reduces the risks of graft rejection and graft-versus-host disease, but may delay posttransplant
immune reconstitution caused by delayed clearance of ATG from the blood. We studied graft-versus-host
disease, infections, and the kinetics of immune reconstitution in 28 patients with very poor-risk hematologic
malignancies who received lymphocyte-depleted, CD34 cell-enriched hematopoietic progenitor cell grafts
from partially HLA-matched related donors (PMRD). The incidence of these clinical events was correlated
with blood ATG levels in 19 transplant recipients who received rabbit ATG (r-ATG, thymoglobulin) during
conditioning. Total r-ATG and the fraction of ATG antibodies that bind human cells (active ATG) were
measured for up to 45 days posttransplantation using enzyme-linked immunosorbent assay and flow cytometry
assays. Three patients received equine ATG (e-ATG; total dose of 60 mg/kg/day), 3 patients received 10 mg/kg
r-ATG, and 22 patients received 6 mg/kg r-ATG during conditioning. All evaluable patients engrafted. Median
numbers of blood CD4 and CD8T cells at 100 days posttransplantation were 15 and 8 cells/L, respectively.
Acute graft-versus-host disease developed in 3 of 3 recipients of e-ATG and 1 of 25 recipients of r-ATG. Rapid
T-cell reconstitution was seen only in younger patients. Overall mortality was 93% (26/28 patients) with poor
immune reconstitution contributing to death in 21 of 28 patients. Recipients of 6 mg/kg r-ATG had peak levels
of total and active r-ATG of 6420 g/mL and 9.25.8 g/mL, respectively, with clearance of active r-ATG
(t1/26 days) to sub-therapeutic levels (<1 g/mL) by a median of 15 days posttransplantation (range, 8-38 days).
Delayed immune reconstitution is likely a consequence of ex vivo and in vivo purging of donor T cells in the
graft coupled with inadequate thymic function rather than persistence of active r-ATG in the blood for months
posttransplantation.
© 2003 American Society for Blood and Marrow Transplantation
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INTRODUCTION
Anti-thymocyte globulin (ATG) is used in the
conditioning regimen in recipients of allogeneic he-
matopoietic progenitor cell (HPC) transplants to de-
plete recipient T cells that could result in graft rejec-
tion as well as to inhibit donor T cells that cause
graft-versus-host disease (GVHD) [1,2]. Commer-
cially available ATG preparations are puriﬁed gamma
immunoglobulin-containing polyclonal antilympho-
cyte antibodies prepared from rabbits (r-ATG) or
horses (e-ATG) hyper-immunized with human thy-
mocytes (thymoglobulin r-ATG; ATGAM e-ATG) or
a cultured human T-cell leukemia cell line (Fresenius
r-ATG). Recent studies indicate that engraftment
rates of greater than 90% and rates of less than 10%
grade 2-4 acute GVHD can be routinely achieved in
T-cell depleted HPC transplants from haplo-type
mismatched partially HLA-matched related donors
(PMRD) using highly immunosuppressive condition-
ing regimens that included Fresenius r-ATG at a dose
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of 25 mg/kg [3] or thymoglobulin r-ATG at doses of
6 to 10 mg/kg [4]. The administration of high-dose
fresenius r-ATG (60-90 mg/kg body weight) before
transplantation resulted in low rates of grade 2-4 acute
GVHD (15%) among adult recipients of volunteer
unrelated donor (VUD) bone marrow transplants [5],
while the addition of 4 to 10 mg/kg thymoglobulin
r-ATG or 10 to 25 mg/kg Fresenius r-ATG to cyclo-
phosphamide-containing conditioning regimens re-
sulted in rates of acute GVHD of 6% and 12% among
pediatric recipients of HPC transplants from related
and unrelated donors, respectively [6]. While this
study used a variety of ATG doses, analyses of residual
ATG in patients’ serum samples obtained 1, 2, or 3
weeks posttransplantation showed 55%, 41%, and
25% inhibition of T-cell proliferation, respectively,
compared with pretransplantation serum samples,
when added to phytohemagglutimin-stimulated
T-cell cultures [6]. Two randomized studies of thy-
moglobulin r-ATG at doses of 7.5 mg/kg or 15 mg/kg
versus placebo administered before a VUD transplan-
tation evaluated the effect of r-ATG on the rate of
GVHD posttransplantation. Recipients conditioned
with 15 mg/kg thymoglobulin r-ATG had a signiﬁ-
cantly lower rate of severe, grade 3-4 acute GVHD
compared with recipients of placebo (11% v 50%),
while treatment with the lower dose of thymoglobulin
r-ATG did not result in a signiﬁcant reduction in
GVHD rates [7]. Of note, long-term overall survival
and event-free survival were equivalent between the
placebo-treated and r-ATG–treated groups because of
increased death from infections among the ATG-
treated patients compared with increased death from
GVHD among the placebo-treated patients [7].
Among recipients of allogeneic mismatched HPC
transplants, posttransplantation administration of e-
ATG was associated with signiﬁcantly delayed recov-
ery of normal blood lymphocyte numbers and func-
tion [2]. These studies suggest that persistence of
active ATG in the blood of allogeneic HPC transplant
recipients may have signiﬁcant posttransplantation in-
hibitory effects on donor T cells in the graft. How-
ever, available studies do not indicate whether the
suppression of T-cell counts in the blood posttrans-
plantation results either from the inhibitory effects of
ATG persisting in the blood on de novo thymic de-
velopment of T cells, or the “in vivo purging” of
donor T cells contained within the graft because of
residual active ATG in the blood on the day of trans-
plantation. A comparison between ATG pharmacoki-
netics (clearance over time) and pharmacodynamics
(biological effect over time) can help answer this ques-
tion.
r-ATG pharmacokinetics depends on the dose and
schedule of administration as well as the number of
lymphocytes in the blood, lymph nodes, and bone
marrow at the time of treatment. The pharmacokinet-
ics of r-ATG have been studied primarily among or-
gan transplant recipients, and clearance of r-ATG was
found to be consistent with single exponential decay
and elimination half-life of 30 days [8]. Studies of the
clearance of r-ATG given before allogeneic HPC
transplant indicated that r-ATG remained in the
blood at signiﬁcant levels for up to 2 months post-
transplantation [8]. However, these studies and most
studies of r-ATG pharmacokinetics have measured
r-ATG in blood samples using an enzyme-lnked im-
munosorbent assay (ELISA) that may signiﬁcantly
overestimate levels of biologically active antibody
molecules [8].
The present study was undertaken to assess the
relationship between biologically active r-ATG and
immune reconstitution in recipients of T-cell depleted
PMRD HPC transplants. We tested the hypothesis
that persistence of pharmacologically signiﬁcant levels
of active r-ATG in the plasma posttransplantation was
a signiﬁcant factor in delayed immune reconstitution
among recipients of PMRD HPC. We monitored
posttransplantation immune reconstitution and pro-
spectively collected r-ATG levels in plasma samples
from 19 patients of 28 sequential recipients of PMRD
HPC transplants between September 1999 and De-
cember 2001. Data presented below indicate that the
type of ATG, the administration of ATG before or
after total body irradiation (TBI) during the condi-
tioning regimen, and the dose of ATG appear to be
important factors on the overall clinical impact of
ATG in allogeneic transplantation. Signiﬁcant deﬁcits
in T-cell reconstitution persisted for more than 6
months posttransplantation among PMRD HPC
transplant recipients, while active r-ATG declined to
subtherapeutic levels by 1 month posttransplantation.
The data presented below indicate that impaired thy-
mopoiesis rather than persistent r-ATG were the pri-
mary cause of delayed T-cell reconstitution among
recipients of PMRD HPC transplant.
METHODS
Patient Population
Between September 1999 and December 2001, 28
adult patients with a median age of 31 years (range,
21-56 years) with very poor-risk hematologic malig-
nancies received blood HPC transplants from PMRD,
matched at 3/6 or 4/6 of the HLA A, B, and DR1 loci
(Table 1). Patients were enrolled on this study because
they lacked a suitable related donor or VUD-matched
at 6/6 HLA loci, or the clinical urgency of the pa-
tient’s disease precluded waiting for HLA-matched
VUD. Family members were assessed for HLA com-
patibility using standard serologic testing for HLA
class I antigens and molecular testing for HLA class II
antigens. The donor was a parent in 8 cases, a sibling
in 10 cases, in 2 cases a male cousin, and in 8 cases a
child of the recipient (Table 1). r-ATG pharmacoki-
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Table 1. Characteristics of Study Population
UPIN
Patient
Age/Sex Diagnosis
Donor
Age Relation
HLA
Match
(GR)
Conditioning
Regimen ATG
ATG
levels
Graft
CD34 /kg
Graft
CD3 /kg
Patient/Donor
CMV Status
1578 40/m ALL CR2 16 Son 3/6,4/6 TBI, TT, FLU 60 mg/kg e-ATG N/D 4.3E  06 5.7E  03 Neg/neg
1587 25/m CML CP2 23 Brother 3/6,3/6 TBI, TT, FLU 60 mg/kg e-ATG N/D 9.8E  06 2.0E  04 Neg/pos
1606 32/m NHL refractory 30 Brother 3/6,4/6 TBI, TT, FLU 60 mg/kg e-ATG N/D 2.4E  07 1.2E  04 Neg/neg
1612 31/m ALL (Ph) CR1 65 Father 4/6,3/6 TBI, TT, FLU 10 mg/kg r-ATG N/D 2.6E  06 5.1E  03 Neg/pos
1617 55/m Myelofibrosis 39 Daughter 4/6,3/6 BU, CY, FLU 10 mg/kg r-ATG Yes 5.6E  06 1.6E  04 Neg/pos
1620 30/m CML CP2 24 Sister 4/6,4/6 TBI, TT, FLU 10 mg/kg r-ATG Yes 1.2E  07 1.9E  04 Neg/pos
1635 39/f AML monoz 7 CR1 12 Son 5/6,3/6 TBI, TT, FLU 6 mg/kg r-ATG Yes 4.5E  06 3.3E  04 Neg/neg
1636 28/m AML CR2 59 Mother 4/6,3/6 TBI, TT, FLU 6 mg/kg r-ATG Yes 9.3E  06 3.0E  04 Neg/pos
1642 45/m AML 5q-CR1 26 Son 3/6,3/6 TBI, TT, FLU 6 mg/kg r-ATG Yes 7.7E  06 1.5E  04 Pos/pos
1665 38/m AML/MDS CR1 48 Brother 4/6,4/6 TBI, TT, FLU 6 mg/kg r-ATG Yes 3.0E  06 4.7E  04 Pos/pos
1671 21/m ALL refractory 42 Mother 3/6,3/6 TBI, TT, FLU 6 mg/kg r-ATG Yes 9.5E  06 1.4E  04 Pos/pos
1675 47/m AML refractory 24 Son 3/6,3/6 TBI, TT, FLU 6 mg/kg r-ATG Yes 5.4E  06 2.5E  03 Pos/pos
1676 23/f AML refractory 51 Father 3/6,3/6 TBI, TT, FLU 6 mg/kg r-ATG Yes 8.6E  06 2.3E  04 Neg/pos
1685 23/m AML refractory 45 Mother 3/6,3/6 TBI, TT, FLU 6 mg/kg r-ATG Yes 1.2E  07 1.4E  04 Neg/pos
1708 48/m ALL (Ph) refractory 27 Daughter 3/6,3/6 TBI, TT, FLU 6 mg/kg r-ATG Yes 1.1E  07 1.1E  04 Pos/neg
1715 29/f AML refractory 52 Mother 3/6, 3/6 TBI, TT, FLU 6 mg/kg r-ATG Yes 6.4E  06 6.3E  03 Pos/pos
1717 21/f AML refractory 52 Mother 3/6, 3/6 TBI, TT, FLU 6 mg/kg r-ATG Yes 1.2E  07 5.5E  03 Pos/pos
1721 26/m AML refractory 31 Brother 3/6,3/6 TBI, TT, FLU 6 mg/kg r-ATG Yes 1.3E  07 5.3E  03 Pos/pos
1723 25/m AML CR2 45 Father 4/6,4/6 TBI, TT, FLU 6 mg/kg r-ATG Yes 4.4E  06 3.1E  04 Pos/pos
1726 21/f AML refractory 27 Brother 4/6,4/6 BU, FLU 6 mg/kg r-ATG Yes 8.4E  06 5.0E  03 Pos/neg
1733 56/m MDS/AML monoz 7 33 Son 3/6,3/6 BU, CY, FLU 6 mg/kg r-ATG Yes 1.6E  07 1.4E  04 Pos/neg
1735 49/m CML BC 22 Son 5/6,5/6 BU, CY, FLU 6 mg/kg r-ATG Yes 6.6E  06 2.8E  04 Pos/neg
1739 25/m AML relapse 32 Cousin (m) 4/6,3/6 TBI, TT, FLU 6 mg/kg r-ATG Yes 1.9E  07 1.4E  04 Pos/pos
1756 44/m AML CR2 55 Brother 2/4,3/4 TBI, TT, FLU 6 mg/kg r-ATG N/D 1.6E  07 3.9E  03 Neg/pos
1767 22/f AML relapse 39 Sister 5/6,4/6 TBI, TT, FLU 6 mg/kg r-ATG N/D 3.0E  06 2.9E  04 Pos/pos
1772 26/f AML relapse 35 Cousin (m) 3/6,5/6 TBI, TT, FLU 6 mg/kg r-ATG N/D 6.4E  06 6.8E  03 Pos/pos
1779 35/m AML CR2 40 Sister 5/6,5/6 TBI, TT, FLU 6 mg/kg r-ATG N/D 8.5E  06 1.0E  04 Pos/pos
1780 31/f AML CR2 30 Brother 4/6,4/6 TBI, TT, FLU 6 mg/kg r-ATG N/D 7.7E  06 4.1E  04 Pos/neg
Median (range) 31 (21-56) 34 (12-65) 8.4E  06
(2.6E  06-
2.4E  07)
1.4 E  04
(2.5E  03-
4.7E  04)
NOTE. Diagnoses included acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and non-Hodgkin’s lymphoma (NHL). Disease states at the
time of transplantation included blast crisis CML (BC), ﬁrst complete remission (CR1), second complete remission (CR2), relapse and refractory (active) disease. Adverse cytogenetic features included
Philadelphia chromosome (Ph), monozomy 7 (monoz 7), and partial deletion chromosome 5 (5q-). The conditioning regimes included total body irradiation (TBI), thiotepa, (TT), ﬂudarabine (FLU),
cyclophosphamide (CY), busulfan (BU), and anti- thymocyte globulins from horses (e-ATG) or rabbits (r-ATG). ND  not determined.
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netics were also performed on a single patient who
received thymoglobulin before receiving a myeloabla-
tive conditioning regimen and HPC transplantation
from a HLA-matched related donor (MRD). The
clinical protocols were reviewed and approved by the
Emory University Institutional Review Board, and
patients and their donors gave informed consent to
participate.
Conditioning Regimens
Twenty-four recipients of PMRD transplants re-
ceived a conditioning regimen consisting of fraction-
ated TBI (1200 cGy in 200-cGy fractions given twice
a day for 3 consecutive days), thiotepa (5 mg/kg every
12 hours for 2 doses), and ﬂudarabine (40 mg/m2daily
for 5 consecutive days) followed by a CD34-selected,
lymphocyte-depleted PMRD blood HPC transplant.
ATG was administered for the last 3 days (e-ATG) or
4 days (r-ATG) of the conditioning regimen. Three
patients who were over the age of 50, and 1 patient
who had previously received TBI, received a condi-
tioning regimen consisting of 16 doses of 1 mg/kg
busulfan every 6 hours for 4 days with ﬂudarabine 40
mg/m2daily for 5 consecutive days and, in the 3 older
patients, 120 mg/kg cyclophosphamide followed by a
CD34-selected, lymphocyte-depleted PMRD blood
HPC transplant (Table 1). The ﬁrst 3 patients re-
ceived e-ATG at a dose of 20 mg/kg daily for 3
consecutive days (total of 60 mg/kg). The subsequent
3 patients received r-ATG (thymoglobulin) at a dose
of 2.5 mg/kg daily for 4 consecutive days (total of 10
mg/kg). The remaining 22 patients received r-ATG at
a dose of 1.5 mg/kg daily for 4 consecutive days (total
of 6 mg/kg). The recipient of a CD34 cell-selected
HPC transplant graft from a 6/6 HLA MRD was a
patient with high-grade T-cell lymphoblastic lym-
phoma who received a conditioning regimen consist-
ing of a total dose of 11.5 mg/kg r-ATG on days 11
to 7 followed by a total of 12 cGy TBI on days 6,
5, 4 and 60 mg/kg cyclophosphamide on day 3
and 2. No posttransplantation immunosuppressive
treatment was given for GVHD prophylaxis for the 28
recipients of PMRD blood HPC grafts or the single
recipient of an MRD blood HPC graft. Supportive
care for the PMRD transplant recipients has been
described [4]. Recipients of PMRD transplants and
r-ATG did not receive posttransplantation granulo-
cyte colony-stimulating factor (G-CSF) or granulo-
cyte-macrophage colony-stimulating factor (GM-
CSF) before day 30. All patients who were evaluable
for engraftment developed full donor chimerism in
peripheral blood lymphocytes.
Blood Hematopoietic Progenitor Cell Grafts
CD34 blood HPC were mobilized from PMRD
with G-CSF 5 g/kg twice daily administered subcu-
taneously for 5 to 9 days (median, 7 days). Leuka-
pheresis was begun on the ﬁfth day of donor G-CSF
therapy and was performed daily. Apheresis products
were processed by a single-step CD34 selection and
negative selection of lymphocytes using monoclonal
antibodies to T cells (anti-CD2 or the combination of
anti-CD4 with anti-CD8) in conjunction with anti-B–
cell antibodies (anti-CD19 and anti-CD20) using
Isolex 300i (Baxter Oncology, Chicago, IL) and soft-
ware version 2.5. There was no difference in the
efﬁciency of T-cell depletion using either anti-CD2
alone or in the combination of anti-CD4 and anti-
CD8 monoclonal antibodies. If more than a single
apheresis was performed, the apheresis products from
the ﬁrst and second day collections were pooled and
processed together. Subsequent apheresis collections
were processed daily and infused until target doses of
a minimum of 5  106 CD34 cells/kg and a maxi-
mum of 5 104 CD3 cells/kg had been infused. The
median numbers (and range) of hematopoietic pro-
genitors and T cells transplanted were 8.4  106
CD34 cells/kg (range, 2.6 1062.4 107 CD34
cells/kg) and 1.4  104 CD3 cells/kg (range, 2.5 
103 4.7  104 CD3 cells/kg), respectively (Table
1). Donors underwent a median of 3 days of apheresis
(range, 1-4 days). The MRD donor graft was collected
and processed in a similar manner using only CD34
selection (without negative selection of CD2/CD19/
CD20 cells) to yield a graft containing 7.7  106
CD34 cells/kg and 7.2  104 CD3 cells/kg.
Measurement of Total and Active Anti-Thymocyte
Globulin
Plasma samples were prospectively collected from
21 patients undergoing PMRD transplantation for
measurements of plasma levels of r-ATG to test the
hypothesis that persistence of r-ATG in the blood
contributed to delayed immune reconstitution post-
transplantation (Table 1) [4]. Thymoglobulin phar-
macokinetics was determined in 19 recipients of
PMRD transplant conditioned with r-ATG (2 pa-
tients died of bacterial sepsis within the ﬁrst week of
transplantation and were not evaluable), and the 1
recipient of a MRD HPC transplant. Plasma samples
were obtained daily from the day preceding r-ATG
administration to day 4 posttransplantation, then on
days 7, 14, 28, 45, 60, 75, and 100 post-
transplantation. Samples were analyzed at Sangstat
(Freemont, CA) for the presence of total rabbit im-
munoglobulin using an ELISA assay, and for the frac-
tion of ATG that retained the capacity to bind to
human lymphocytes (active ATG) according to the
methods described by Regan et al [9]. Brieﬂy, an
ELISA assay (PraStat; Sangstat) of patient serum sam-
ples was performed to measure the quantity of rabbit
immunoglobulin using plates coated with 10 g/mL
goat anti rabbit IgG (H  L) that had been absorbed
for minimal cross-reactivity to human serum proteins
(JackSon Laboratories, Bar Harbor, ME). Bound rab-
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bit immunoglobulin was revealed using the capture
antibody conjugated with horseradish peroxidase and
a colorimetric o-phenylenediamine reagent. Relative
amounts of active r-ATG were determined using a
ﬂow cytometry assay; 5 105 human peripheral blood
mononuclear cells (PBMC) were incubated with 50
L of patient serum samples diluted 1:15 into phos-
phate-buffered saline containing 1% v/v bovine serum
albumin and 0.01% sodium azide for 30 minutes at
4°C in V-bottom 96-well plates (NUNC, St. Louis,
MO). Following washing, the PBMC were incubated
with biotinylated goat anti-rabbit immunoglobulin
(human, mouse, and rat immunoglobulin cross-reac-
tivity absorbed) and ﬂouroscein isothio cyanin–avidin.
The level of ﬂuorescence staining on gated lympho-
cytes was determined by ﬂow cytometry. This assay
shows a linear relationship between the log[mean ﬂu-
orescence intensity] and the log[thymoglobulin con-
centration] in the range 0.1 to 50 g/mL [9]. Anti-
thymocyte globulin levels were not measured among 3
recipients of e-ATG.
Measurement of Blood Lymphocytes and Immune
Reconstitution
The content of T cells in the blood of recipients of
TBI-based conditioning and r-ATG was assessed on
day 10 (before conditioning), on day 4 (before
r-ATG and after TBI), and on day 0 (before trans-
plantation). Flourescent activated cell sorting (FACS)
was used to assess mean numbers of CD3 cells in the
peripheral blood on samples ﬁxed with paraformalde-
hyde. In addition, unﬁxed PBMC samples on day 4
and day 0 were stained with anti-CD3 and propidium
iodide to calculate the fraction of “viable” CD3 (pro-
pidium iodide negative) cells. The frequency of func-
tional T cells was evaluated with a limiting dilution
assay that measured T-cell proliferation. Ninety-six–
well microtiter plates were coated with anti-CD3
monoclonal antibody (OKT3) 10 g/mL for 1 hour at
37°C, then washed with phosphate buffered saline.
Mononuclear cells from patient blood samples or con-
trol blood samples from a normal donor were pre-
pared by gradient centrifugation using Lymphocyte
Separation Medium (Mediatech, Inc, Herndon, VA).
Serial dilutions of mononuclear cells, in replicates of
10, were incubated with 5  104 irradiated (2500 Gy)
allogeneic lymphocytes for 12 days in RPMI with 10%
fetal calf serum. IL-2 (PeproTech, Inc, Rocky Hill,
NJ) was added to a concentration of 10 /mL on day
3, an additional 5  104 irradiated (2500 Gy) alloge-
neic lymphocytes and 50 /mL IL2 were added on
day 7. T-cell proliferation in each well was assessed by
the addition of 1 Ci 3H thymidine on day 11 of
culture; the amount of 3H thymidine incorporated
into DNA was measured on day 12. Poisson analysis
was used to calculate the frequency of wells containing
proliferating T cells. Peripheral blood samples were
obtained on days 14, 28, 45, 60, 75, 100, 6
months, and every 6 months posttransplantation. The
content of CD4 and CD8 T cells, CD56 natural
killer (NK) cells, and CD19 B-cells/L blood was
assessed by multiparameter ﬂow cytometry using
monoclonal antibodies and an FACS scan purchased
from Becton Dickinson (San Jose, CA) using standard
methods previously described [10]. The diagnosis and
degree of acute and chronic GVHD was assessed ac-
cording to consensus criteria [11].
RESULTS
Demographics of the Study Population of Partially
HLA-Matched Related-Donor Hematopoietic
Progenitor Cell Transplantation
Twenty-eight adult patients, age 21 to 56 years,
were entered onto a phase I study of myeloablative
conditioning using modiﬁcations of the “Perugia”
conditioning regimen and transplantation with
CD34 selected, T-cell depleted blood HPC grafts
from PMRD [4]. Active relapsed or refractory malig-
nancies were present at the time of transplantation in
15 of 28 patients, including 10 patients with relapsed/
refractory acute myeloid leukemia (AML), 2 with re-
fractory acute lymphoblastic leukemia (ALL), 1 pa-
tient with chronic myeloid leukemia (CML) in blast
crisis, 1 patient with myeloﬁbrosis, and 1 with refrac-
tory non-Hodgkin’s lymphoma (NHL) (Table 1). The
remaining patients had high-risk acute leukemia in
remission (5 AML in second complete remission and 2
ALL patients in complete remission), or AML in ﬁrst
complete remission with unfavorable prognostic fea-
tures (4 patients with antecedent myelodysplasia or
poor-risk cytogenetic abnormalities) (Table 1).
Twenty of 28 patients were male. The 24 recipients of
the TBI-based conditioning regimen were younger
(median age 29; range, 21-48 years) compared with
the 4 recipients of the busulfan-based conditioning
regimen (median age, 52 years). The initial 3 patients
entered on this study received e-ATG at a dose of 20
mg/kg daily for 3 days (total dose 60 mg/kg) in com-
bination with a TBI-based conditioning regimen. The
protocol was subsequently amended to more closely
conform to the “Perugia” regimen, substituting r-
ATG for e-ATG. The diagnoses and demographics of
patients who received e-ATG (AML, ALL, and CML
chronic phase 2; median age, 32 years) were similar to
the patients who received r-ATG (median age, 30
years; Table 1).
Conditioning Regimen Ablated Viable Host
T Cells and Permitted Donor Hematopoietic
Progenitor Cell Engraftment
The immunosuppressive effect of r-ATG and the
conditioning regimen was assessed by the content of
peripheral blood CD3 T cells. The T-cell content of
the blood was measured on day 10 (before initiation
E. K. Waller et al.
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of the conditioning regimen), on day 4 (following
TBI and before administration of r-ATG) and on day
0 (before donor HPC infusion). The mean number of
blood T cells as assessed by routine FACS on ﬁxed
samples declined from 840 CD3 cells/L on day
10 to 15 CD3 cells/L on day 4, to 17 CD3
cells/L on day 0 (Table 2). Using a measurement of
“viable” T cells in the blood with FACS and the vital
dye propidium iodide, the content of viable host
CD3 cells was 6 CD3 cells/L on day 4 and 1
CD3 cell/L on day 0 (Table 2). Using limiting-
dilution culture of PBMC isolated from 100 mL of
blood obtained from 5 recipients of the TBI-based
conditioning regimen and 4 recipients of the busulfan-
based conditioning regimen, the number of viable
mononuclear cells obtained after Ficoll Hypaque cen-
trifugation of 100 mL of peripheral blood on day 0
was100 000; no patient had detectable clonogenic T
cells in their blood (frequency of T cells 1 cell per
10 000 viable blood lymphocytes; data not shown).
Graft-versus-Host Disease and T-Cell
Reconstitution after Partially HLA-Matched
Related Donor Transplantation
All 3 recipients of e-ATG developed acute GVHD
that required treatment with immuno-suppressive
drugs: 1 patient with grade 1 acute GVHD (stage 1
skin and stage 1 upper gastrointestinal treated with
steroids), 1 patient with grade 2 acute GVHD (stage 3
skin and stage 1 lower gastrointestinal treated with
steroids), and 1 patient with grade 3 acute GVHD
(stage 3 skin and stage 2 lower gastrointestinal treated
with steroids and tacrolimus). The patient with grade
3 acute GVHD developed chronic extensive GVHD,
became intolerant to tacrolimus, and required long-
term treatment with mycophenolate mofetil and ste-
roids (Table 3). One of the 25 recipients of r-ATG
required systemic treatment with steroids for grade 2
acute GVHD (stage 3 skin, stage 2 lower gastrointes-
tinal). The kinetics of T-cell reconstitution was sig-
niﬁcantly different between the 3 recipients of 60
mg/kg e-ATG and the 25 recipients of r-ATG. Figure
1 compares the mean number of blood CD4 and
CD8 T cells in recipients of 60 mg/kg e-ATG to 22
recipients of 6 mg/kg r-ATG. Recipients of e-ATG
had signiﬁcantly higher mean numbers of blood
CD3 cells in the ﬁrst 30 days posttransplantation
than recipients of 6 mg/kg r-ATG. The kinetics of
T-cell reconstitution among the 4 recipients of 10
mg/kg r-ATG was not signiﬁcantly different from
recipients of 6 mg/kg r-ATG (data not shown). The
mean CD4 and CD8 T-cell counts in the blood fell
among the recipients of e-ATG between 30 and 100
days posttransplantation during treatment for acute
GVHD and gradually rose among recipients of r-
ATG. By 6 months posttransplantation, recipients of
r-ATG had higher blood T-cell counts than recipients
of e-ATG (Figure 1).
Kinetics of Natural Killer Cell and B-Cell
Reconstitution Were More Rapid than T-Cell
Reconstitution among Recipients of r-ATG
While peripheral blood T-cell counts were se-
verely suppressed for the ﬁrst 6 months posttransplan-
tation among recipients of r-ATG, blood B cells and
NK cells appeared in the blood at much higher fre-
quencies during the same period (Figure 2). Natural
killer cells were the predominant blood lymphocyte
during the ﬁrst 100 days posttransplantation, with
peak values of 1500 NK cells/L observed among
some recipients of r-ATG during the ﬁrst 100 days
posttransplantation. B-cell reconstitution occurred
more gradually during this period, while total num-
bers of CD3 cells increased even more slowly during
the ﬁrst 100 days posttransplantation. The very slow
reconstitution of T cells among recipients of r-ATG
suggested the possibility that residual active r-ATG in
the blood inhibited thymopoiesis in the early post-
transplantation period.
r-ATG Pharmacokinetics in Allogeneic
Hematopoietic Progenitor Cell Transplantation
Recipients of the PMRD blood HPC grafts re-
ceived r-ATG during the latter part of the condition-
ing regimen, immediately before donor cell infusion
based on the published schema from the transplanta-
tion group in Perugia [4]. One important aspect of the
use of ATG in conditioning is the timing of ATG
administration relative to the rest of the conditioning
regimen and the allograft infusion. r-ATG levels were
measured in a recipient of a CD34-selected MRD
Table 2. Depletion of Host T Cells by the Conditioning Regimen
Day WBC/L Lymphocytes/L Total CD3/L Viable CD3/L Clonogenic T Cells/L
Day-10 7900  1900 840  750 692  630 ND ND
Day-4 990  890 64  72 15  32 6  8 ND
Day 0 200  180 161  248 17  42 1  1 <.00001
NOTE: The numbers of peripheral blood white blood cells, lymphocytes, and T cells were determined by a combination of complete blood
counts and ﬂow cytometry. The number of viable T cells was determined by ﬂow cytometry using propidium iodide and an electronic gate
on viable CD3 T cells. The number of clonogenic T cells was determined by limiting-dilution assay of PBMC cultured in plates coated with
anti–T-cell receptor complex antibody (OKT3) and in media containing IL2.
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HPC transplant who received a total dose of 11.5
mg/kg r-ATG before starting the conditioning regi-
men in escalating doses of 0.5, 1, 2, 4, and 4 mg
r-ATG/day on day 11 through day 7 followed by
12 Gy TBI (day 6 through 4) and 120 mg/kg
cyclophosphamide (day 3 and 2). Peak levels of
total and active r-ATG of 176.2 mg/kg and 16.3
mg/kg were obtained immediately following the last
r-ATG infusion on day 7. Repeat r-ATG measure-
ments on day 4 showed total and active r-ATG
levels to have declined to 68.4 and 4.0 mg/mL, re-
spectively, with further declines to 53.3 and 2.1 mg/
mL, respectively, on the day of transplantation (Figure
3A). Plasma levels of total and active ATG subse-
quently declined with ﬁrst order kinetics in this pa-
tient with calculated half lives of 15 and 7 days, re-
spectively (Figure 3B). Of note, this patient engrafted
rapidly with full donor chimerism and developed
grade 3 acute GVHD at 30 days following transplan-
tation of a T-cell–depleted HPC from an MRD that
contained 72  103 CD3 cells/kg.
Levels of total and active r-ATG were measured in
Table 3. Clinical Outcomes of Patients in Study Population
UPIN
Acute GvHD:
Grade (Stage)
Chronic
GVHD GvHD Treatment
CMV
Reactivation Status
Follow-Up
(Days) Cause of Death
1578 Grade 1 (Skin 1;
GI 1; Liver 0)
No Steroids No Alive 1220 (Alive in remission)
1587 Grade 3 (Skin 3;
GI 2; Liver 0)
Yes Steroids, tacrolimus,
MMF
No Dead 232 Sepsis
1606 Grade 2 (Skin 3;
GI 1; Liver 0)
No Steroids No Dead 306 Primary disease
1612 0 No No Dead 6 S viridans sepsis
1617 0 No No Dead 69 EBV LPD
1620 0 No Day 20 Alive 1066 (Alive in remission)
1635 0 No No Dead 976 Fungal pneumonia;
hemolytic anemia
1636 0 No No Dead 143 Primary disease
1642 0 No Day 33 Dead 144 Primary disease
1665 0 No No Dead 109 Bacterial pneumonia
1671 Grade 2 (Skin 3;
GI 2; Liver 0)
No Steroids Day 20 Dead 73 Fungal infection
1675 0 No Day 27 Dead 42 Fungal pneumonia
1676 0 No No Dead 124 Primary disease
1685 0 No No Dead 8 S viridans sepsis
1708 0 No No Dead 29 Diffuse alveolar damage
1715 0 No Day 26 Dead 205 Pneumocystis and CMV
pneumonia
1717 0 No Day102 Dead 171 Primary disease
1721 0 No No Dead 89 Primary disease
1723 0 No Day 38 Dead 631 Primary disease
1726 0 No No Dead 119 Graft rejection
1733 0 No Day 32 Dead 171 Viral pneumonia; EBV
LPD
1735 0 No Day 32 Dead 106 Fungal infection
1739 0 No Day 42 Dead 122 Primary disease
1756 0 No No Dead 145 Amoebic encephalitis
1767 0 No Day 46 Dead 149 Unknown, died in sleep
1772 0 No No Dead 66 Pulmonary failure
1779 0 No Day 32 Dead 121 Liver failure-not VOD
1780 0 No Day 24 Dead 58 Toxoplasmosis
Abbreviation: MMF, mycophenylate mofetil.
Figure 1. Higher numbers of peripheral blood T cells in PMRD
transplant recipients conditioned with e-ATG versus r-ATG. Mean
numbers (with SD error bars) of CD4 and CD8 T cells in the
blood of PMRD transplant recipients conditioned with 60 mg//kg
e-ATG (n3; dashed lines) were compared with mean numbers of
circulating T cells in PMRD transplant recipients conditioned with
6 mg/kg (n21) r-ATG (solid lines).
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19 evaluable recipients of PMRD HPC transplants
who received r-ATG as part of the conditioning reg-
imen immediately following TBI (or busulfan) and
overlapping with ﬂudarabine administration [4]. The
pharmacokinetics of r-ATG in a typical PMRD trans-
plant recipient who received a total dose of 10 mg/kg
r-ATG during the conditioning regimen is shown in
Figure 2B. Of note, peak levels of 86.2 g/mL total
r-ATG and 30.9 g/mL active r-ATG were obtained
on the day of transplantation. Total and active r-ATG
declined with similar ﬁrst order kinetics as seen in the
recipient of the MRD HPC graft with half-lives of 11
and 7 days, respectively (Figure 3B). The peak levels
and clearance rates of total and active r-ATG were
determined in the entire cohort of 19 evaluable recip-
ients of r-ATG. Relative values of plasma r-ATG were
determined for each patient based on the proportion
of the r-ATG in the sample with the peak level of
r-ATG obtained on day 0. Two phases of clearance
were observed for both total and active r-ATG (Figure
4). Plasma r-ATG had an early alpha clearance during
the ﬁrst 4 weeks posttransplantation, with calculated
half-lives of 7 days (active r-ATG) and 14 days (total
r-ATG). The subsequent beta clearance was identical
for total and active r-ATG with calculated half-lives of
30 and 29 days, respectively (Figure 4).
The pharmacokinetics of r-ATG clearance was
compared between the 2 evaluable recipients of 10
mg/kg r-ATG and the 17 evaluable recipients of 6
mg/kg r-ATG. Peak levels of total r-ATG were sim-
ilar between the 2 groups (Table 4), but peak levels of
active r-ATG on day 0 were signiﬁcantly higher
among recipients of 10 mg/kg (25  8 g/mL) versus
recipients of 6 mg/kg (9.2  5.8 g/mL; P  .002). In
vitro studies have shown complement-mediated lysis
of T cells by high concentrations of thymoglobulin
(100-1000 g/mL) with antibody-dependent cell-me-
diated cytotoxicity and Fas-mediated apoptosis at thy-
moglobulin concentrations of 1 to 10 g/mL [12].
Thus, serum levels of less than 1 g/mL are not likely
to have any signiﬁcant effect on depleting T cells from
the circulation. The time for active r-ATG to decline
to a sub-therapeutic level (1 g/mL) was signiﬁ-
cantly shorter among recipients of 6 mg/kg (17 days)
versus recipients of 10 mg/kg (45 days; P  .002;
Table 4).
Figure 2. Delayed immune reconstitution among recipients of
r-ATG and PMRD transplantation. Mean levels of blood CD56
NK cells (squares), CD3 T cells (diamonds), or CD19 B-cells
(circles) were determined by ﬂow cytometry for recipients of
PMRD transplants treated with 6 mg/kg r-ATG (n21). SD of the
mean values are shown as error bars.
Figure 3. Effect of ATG timing on GVHD in CD34 selected blood HPC transplant recipients. Plasma levels of total (upper lines) and active
(lower lines) of r-ATG were measured in a recipient of a CD34-selected blood HPC graft from a HLA-matched sibling conditioned with
a total of 11.5 mg/kg ATG (black bar) before 12 Gy TBI and 120 mg/kg cyclophosphamide (grey bar; panel A), or a recipient of a
CD34-selected, CD2-depleted blood HPC graft from a partially matched (haplo-identical) sibling conditioned with 12 Gy TBI, 10 mg/kg
thiotepa and 200 mg/kg ﬂudarabine (grey bar) followed by 10 mg/kg ATG (black bar; panel B).
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Opportunistic Infections and Relapse after
Partially HLA-Matched Related Donor Transplant
The recipients of PMRD transplants had very
low numbers of circulating T cells, increasing their
risk for posttransplantation opportunistic infections
and relapse [2]. Nine deaths were caused by oppor-
tunistic infections, including 4 cases of fungal pneu-
monia, 2 cases of Epstein-Barr virus lymphoprolif-
erative disorders, and 1 case each of pneumocystis
pneumonia, toxoplasmosis, and central nervous sys-
tem amoebiasis (Table 3). An additional 4 patients
died of bacterial infections and 8 patients died with
progression or recurrence of their primary malig-
nancy (Table 3). The overall mortality was 93% on
this study, with a median survival of 123 days. These
outcome data are worse than the outcomes reported
from Perugia, but not inconsistent with the absence
of KIR mis-matched donors for most recipients [13]
and the very poor-risk patients with relapsed and
refractory leukemia entered on this phase I study.
We have previously reported the high incidence of
nonfatal acyclovir-resistant herpes simplex virus in-
fections, seen in 7 of 14 recipients of PMRD trans-
plants who had reactivation of herpes simplex virus
posttransplantation at a median of 40 days post-
transplantation [14]. Adding high-dose prophylactic
valacyclovir in the posttransplantation period sub-
stantially reduced the incidence of mucocutaneous
herpes simplex virus (data not shown). Of note, the
overall frequency of cyctomegalovirus (CMV) sero-
positivity pretransplantation among the 56 donors
and recipients was 66% (Table 1). Patients were
monitored weekly for the presence of CMV in the
blood using a sensitive reverse transcriptase poly-
merase chain reaction assay capable of detecting 400
copies/mL [15]. Cytomegalovirus reactivation was
Figure 4. Clearance of total and active r-ATG. The fraction of the day 0 peak level of total and active r-ATG were calculated for each recipient
of PMRD transplant for each time point pre- and posttransplant (n19).
Table 4. Levels of Total and Active Anti-Thymocyte Globulin in Recipients of Partially HLA-Matched Related Donor Transplants
Dose ATG
P value6 mg/kg 10 mg/kg
Day 0 total ATG 62  22 g/mL 77  14 g/mL .4
Day 0 active ATG 9.2  5.8 g/mL 25  8 g/mL .002
T1/2 (early) active ATG 6.3  1.9 days 7.6  1 days .4
Days to <1 g/ml 17  9 days 35  4 days .01
NOTE: Plasma levels of rabbit immunoglobulin (total ATG) were measured by an ELISA assay. Active ATG was calculated as the
concentration of thymoglobulin preparation that gave equivalent levels of binding to human lymphocytes in a ﬂow cytometry assay (see
Methods). Mean peak levels were calculated from recipients of 10 mg/mL thymoglobulin (n  2) or 6 mg/kg thymoglobulin (n  17). The
mean half-lives and days to reach levels of 1 g/mL were calculated from plots of log [ATG concentration] versus days posttransplant
generated for each PMRD transplant recipient.
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seen in 13 of 28 PMRD transplant recipients at a
median of 32 days posttransplantation. All patients
received pre-emptive antiviral therapy, yet 1 patient
developed concomitant CMV and Pneumocystitis ca-
rinii pneumonia. (Table 3) Cytomegalovirus reacti-
vation occurred in 9 of 12 pairs in which both donor
and recipient were CMV sero-positive, in 3 of 5
cases in which only the recipient was positive, in 1
of 8 cases in which only the donor was sero-positive,
and in 0 of 3 cases in which both donor and recip-
ient were sero-negative (Table 3). The rate of CMV
reactivation in both recipient positive groups
(D/R and D/R) was slightly higher than
generally reported after allogeneic transplant, while
the low rate seen in the D/R group is compara-
ble to the study by Nichols et al [16].
DISCUSSION
This study describes immune reconstitution and
clinical outcomes in 28 recipients of CD34 HPC
grafts from PMRD and the pharmacokinetics of total
and active r-ATG in 19 patients who received r-ATG
as part of the conditioning regimen. The 19 patients
in whom serum samples were analyzed for r-ATG
content represent the largest series of allogeneic HPC
transplant patients with detailed ATG pharmacoki-
netics described to date; these patients had similar
characteristics and clinical outcomes to the entire
group of 25 patients treated with r-ATG. We con-
ﬁrmed high engraftment rates using modiﬁcations of
the myeloablative Perugia conditioning regimen and
CD34 selected HPC grafts [3,4] but found signiﬁ-
cant differences in the rates of acute GVHD between
recipients of e-ATG and r-ATG. This series of
PMRD transplants is notable for the high rates of
posttransplantation mortality; nearly two thirds of the
deaths were caused by relapse and opportunistic in-
fections. The high overall mortality observed among
the patients entered on this phase I study is not out of
proportion with the outcomes expected for these very
poor-risk patients with relapsed and refractory leuke-
mia and lymphoma and the absence of KIR mismatch-
ing for over half the patients [13]. The clinical evi-
dence of a profound deﬁcit in cellular immunity is
corroborated by the severe delays in achieving blood
T-cell counts of 200/L in the ﬁrst 6 months post-
transplantation. Analysis of the clearance of total and
active r-ATG posttransplantation, coupled with mea-
surements of circulating blood lymphocytes provided
insights into the factors that regulate immune recon-
stitution in the setting of PMRD HPC transplants.
Acute GVHD occurred in only 1 of 25 recipients
of r-ATG (4% incidence), suggesting that the combi-
nation of ex vivo T-cell depletion using the Isolex
version 2.5 positive/negative selection device and r-
ATG during conditioning were effective as GVHD
prophylaxis in the setting of haplotype-matched HPC
transplants. Measured blood levels of active r-ATG on
the day of transplantation were an average of 9 g/mL
(range, 3 g/mL-21 g/mL) among recipients of 6
mg/kg, a level that could result in in vivo depletion of
the circa 1  106 total donor T cells contained within
the HPC graft via Fas-mediated apoptosis and anti-
body-dependent cell mediated cytotoxicity [12]. Thus
persistence of r-ATG in the immediate posttransplan-
tation setting appears to have a signiﬁcant role as
prophylaxis against acute GVHD by in vivo T-cell
purging. This observation is supported by the devel-
opment of acute GVHD in the single patient who
underwent transplantation with a T-cell depleted
MRD HPC graft who received 11.5 mg/kg r-ATG
before beginning a myeloablative TBI-cyclophospha-
mide conditioning regime in whom levels of active
r-ATG had fallen to 2 g/mL on the day of trans-
plantation. Of note, the single recipient of a CD34
cell-selected graft from a PMRD who received 6
mg/kg r-ATG during conditioning who subsequently
developed grade 2 acute GVHD (UPIN 1671) re-
ceived a similar number of T cells in the graft (1.4 
104 T cells/kg) and had a similar peak level of active
r-ATG (12 g/mL) and clearance rate of active r-
ATG (t1/2 of 8 days) compared with the patients who
did not develop acute GVHD (Tables 1 and 3). Thus,
there remain undeﬁned factors that regulate the de-
velopment of acute GVHD in this setting.
A direct determination of whether residual r-ATG
in the blood inhibits thymopoieis cannot be made
easily in patients, but a number of facts suggest alter-
native explanations for the profound delays observed
in posttransplantation immune reconstitution. First,
r-ATG does not penetrate into the thymus following
intravenous administration of high-dose thymoglobu-
lin in cynomologous monkeys [17], and a direct cyto-
toxic effect of r-ATG (at the lower levels observed
posttransplantation) on developing thymocytes in the
human thymus is thus unlikely. We initially hypoth-
esized that residual ATG in the blood could inhibit
the survival of new T cells derived from donor HPC
in the recipient thymus or the de novo generation of T
cells from extra-thymic sites. The pharmacokinetic
data show log-linear clearance of both total r-ATG
(t1/2 of 14 days) and active r-ATG (t1/2 of 7 days)
during the ﬁrst month posttransplantation. Pharma-
cokinetic analysis of r-ATG levels in 19 recipients of
PMRD blood HPC transplants showed that active
r-ATG levels had generally declined to subtherapeutic
levels of 1 g/mL [12] by day 30 posttransplanta-
tion, while signiﬁcant numbers of T cells (100/L)
did not appear in the blood until at least day 60
posttransplantation. There were no signiﬁcant corre-
lations between the kinetics of T-cell reconstitution
and the peak levels of active r-ATG on day 0; the
half-life of active r-ATG; or the time for the level of
active r-ATG to fall to less than 1 g/mL (data not
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shown). Thus, the cause for delayed immune recon-
stitution among recipients of PMRD transplants re-
mains an important question. One clue is that the
appearance of T cells in the blood by day 100 post-
transplantation was signiﬁcantly associated with the
age of the transplant recipient. Among the 7 recipients
of r-ATG aged 25 or less, 5 of 7 patients had 100
CD3 T cells/L in their blood by day 100 post-
transplantation (median maximum CD3 cells/L of
102; Figure 5), while only 1 of the 14 r-ATG recipi-
ents aged 26 or greater had more than 100 CD3 T
cells/L in their peripheral blood during the same
time interval (median maximum CD3 cells/L of 9;
P  .0003). Matching the age of the donor with the
kinetics of posttransplantation T-cell recovery showed
no relationship because many of the youngest patients
with the most rapid recovery of peripheral blood T
cells had (older) parents as donors (Figure 5). In con-
trast, we found no relationship of patient age with the
kinetics of B-cells or NK cell recovery in the ﬁrst 100
days posttransplantation (data not shown). The data
presented in Figure 4, interpreted in the context of the
data from Mackall et al. [18] showing that thymic
function is inversely correlated with age, indicate that
residual thymic function of PMRD transplant recipi-
ents is an important factor in determining the speed of
recovering circulating blood T cells, and, by exten-
sion, normalization of cellular immune functions.
While administration of G-CSF before myeloid en-
graftment has been shown to be associated with re-
duced numbers of blood CD4 T cells and increased
numbers of inhibitory type 2 dendritic cells in recip-
ients of PMRD [19], none of the recipients of r-ATG
in the current study received G-CSF or GM-CSF in
the immediate posttransplantation period. Future ap-
proaches to enhance recovery of cellular immunity in
this patient population will need to be focused either
at enhancing endogenous thymic function [20] or de-
velop methods of adoptive cellular immunotherapy
that transfer antigen-speciﬁc T cells with limited po-
tential to cause GVHD [21-23].
We found a higher incidence (100%) of acute
GVHD and more rapid initial T-cell reconstitution
among the 3 transplant recipients who received e-
ATG during conditioning compared with a very low
incidence of acute GVHD (4%) and delayed T-cell
recovery among 25 recipients of 6 to 10 mg/kg r-ATG
(P .001). The lack of pharmacokinetic data for e-
ATG precludes a direct comparison between clear-
ance of active e-ATG and r-ATG, and only 3 patients
received e-ATG in this study. However, the signiﬁ-
cantly higher numbers of T cells measured in the
blood during the immediate posttransplantation pe-
riod among recipients of e-ATG compared with re-
cipients of r-ATG (Figure 1) and the differences in the
incidence of acute GVHD between recipients of e-
ATG and r-ATG suggest signiﬁcant differences in the
pharmacodynamics between the 2 different ATG
preparations. The increased survival of donor T cells
following infusion of the HPC graft among recipients
of e-ATG indicate either that (1) 6 to 10 mg/kg
r-ATG resulted in higher titers of anti T-cell antibod-
ies than 60 mg/kg e-ATG; (2) active r-ATG has a
signiﬁcantly longer half-life in the blood of transplant
recipients than e-ATG; or a combination of both
factors. While higher doses of e-ATG administered
during conditioning could be equally effective in pre-
venting the development of GVHD as 6 to 10 mg/kg
r-ATG, answering this question would require a di-
rect comparison of the incidence of GVHD and clear-
ance of active e-ATG and r-ATG in equivalent groups
of patients receiving both products, and is beyond the
scope of the present report. Additional studies will be
needed to deﬁne the minimum plasma concentration
of active r-ATG on the day of transplantation neces-
sary for in vivo purging to prevent the development of
acute GVHD in the setting of T-cell depleted MRD
and PMRD transplants. Future clinical trials can be
designed to address this question using targeted values
for day 0 levels of active ATG based on the low
incidence of acute GVHD in the patients who re-
ceived 6 mg/kg r-ATG in whom mean day 0 (peak)
levels of active r-ATG were 9	 6 g/mL (range, 3-21
g/mL).
In summary, these data indicate the persistence of
active r-ATG posttransplantation was probably not
responsible for delayed T-cell reconstitution seen in
these patients. However, the presence of circulating
r-ATG on the day of the allograft transplantation does
appear to be important in the prevention of acute
GVHD after allogeneic blood HPC transplantation in
the absence of posttransplantation immunosuppres-
sion. The likely hypotheses to explain the severely
delayed cellular immunity seen in the PMRD trans-
plant recipients is the lack of donor T cells in the graft
and in vivo purging effect of residual r-ATG in the
blood on the day of transplantation coupled with poor
thymic function in the recipient. The present study
shows that T-cell depletion of PMRD HPC trans-
Figure 5. Relationship between donor/recipient age and T-cell
recovery posttransplantation.
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plants and conditioning regimens that include r-ATG
are effective in preventing posttransplantation
GVHD, but delays in the reconstitution of cellular
immune remains a signiﬁcant problem that will limit
the overall success and clinical application of PMRD
transplants.
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